Enanta Pharmaceuticals Inc. (9EP)
XDUS 
Summary
9EP Chart
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.06 per share a year ago.
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Enanta Pharmaceuticals Inc. (9EP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Enanta Pharmaceuticals Inc. ever had a stock split?
Enanta Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jay R. Luly CEO | XDUS Exchange | US29251M1062 ISIN |
| US Country | 131 Employees | - Last Dividend | - Last Split | 21 Mar 2013 IPO Date |
Overview
Enanta Pharmaceuticals, Inc. is a biotechnology firm engaged in the discovery and development of small molecule drugs, focusing on viral infections and liver diseases. This company leverages its expertise in chemistry and biology to create therapies that aim to address significant unmet medical needs. With a history dating back to its incorporation in 1995, Enanta has established itself in the pharmaceutical landscape, showcasing a commitment to advancing healthcare through innovation. Headquartered in Watertown, Massachusetts, the company collaborates with industry giants like Abbott Laboratories, indicating its strategic approach to development, manufacture, and commercialization of key pharmaceutical products.
Products and Services
Enanta Pharmaceuticals, Inc. boasts a diverse product pipeline targeting various infectious diseases, with efforts anchored in rigorous clinical development stages:
- EDP-514: Currently in phase 1b clinical development, EDP-514 represents Enanta's endeavor to combat chronic hepatitis B virus (HBV) infection. This product underscores the company's commitment to tackling HBV, a significant global health challenge.
- EDP-938 and EDP-323: These compounds are in phase II clinical development aimed at addressing respiratory syncytial virus (RSV) infections. RSV is a common respiratory virus that poses severe risks in infants and the elderly, highlighting the importance of Enanta's work in this area.
- EDP-235: Focused on the treatment of human coronaviruses, EDP-235 is in phase II clinical development. Given the global impact of coronavirus diseases, this initiative by Enanta could contribute significantly to controlling pandemics and outbreaks of respiratory illnesses.
- Glecaprevir: A market-ready product, Glecaprevir, is used for the treatment of chronic hepatitis C virus (HCV) infection. It stands as a testament to Enanta's successful journey from drug discovery to commercial availability, offering a solution for HCV, a major cause of liver disease worldwide.
Through its collaboration with Abbott Laboratories, Enanta has also been able to develop and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. This partnership exemplifies the company's strategic collaborations aimed at enhancing and broadening the impact of its innovative treatments.
